Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + INCB Combinations in Advanced Solid Tumors
NCT02646748Phase 1Completed
- Sponsor
- Incyte
- Start
- Jan 2016
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of itacitinib and parsaclisib in Solid tumors, small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC) and 1 more (2 arms), sponsored by Incyte. Primary endpoint: Evaluation of safety and tolerability. Started Jan 2016; status: completed.
02
Drugs
itacitinibparsaclisib
03
Conditions
Solid tumorssmall cell lung cancer (SCLC)non-small cell lung cancer (NSCLC)urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT02646748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02646748.